NEW YORK (TheStreet) -- Shares of Gilead Sciences (GILD) - Get Report are up by 0.31% to $102.83 in early afternoon trading on Friday, after the company's hepatitis C treatment prescription totals from the previous week were published today, according to Barron's.
UBS analyst Matthew Roden published a note showing that scripts for the company's Harvoni treatment rose 13% over the previous week.
Total scripts for Harvoni and its partner treatment Sovaldi were also up 13% week over week to 9,135.
Two week's ago, Gilead's prescription numbers showed that Harvoni scripts declined 2%, while combined prescriptions of Sovaldi and Harvoni also fell 2% to 9,015.
Separately, TheStreet Ratings team rates GILEAD SCIENCES INC as a Buy with a ratings score of A+. TheStreet Ratings Team has this to say about their recommendation:
We rate GILEAD SCIENCES INC (GILD) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.